Selective FFA2 agonism appears to act via intestinal PYY to reduce transit and food intake, but does not improve glucose tolerance in mouse models. Currently the most effective anti-obesity treatment is bariatric surgery which leads to rapid, long-lasting diabetes remission independent of weight loss (1) . The increased mortality and expense burden associated with obesity and its co-morbidities, including type-2 diabetes, highlights the need for development of knifeless therapeutic strategies. Host-microbiome chemosensation is emerging as an important system in the development and pathogenesis of metabolic syndrome and associated diseases (2) (3) (4) . Indeed the colonic microbial composition is altered following Roux-en-Y gastric bypass (RYGB) and is coupled with improved glucose tolerance, reduced adiposity and weight loss in humans (5) and mice (6).
Short-chain fatty acids (SCFAs) are generated by bacterial fermentation of colonic dietary fibre, reaching high concentrations (70 -130 mM) under physiological conditions in humans (7) . These endogenous ligands activate two free fatty acid (FFA) receptors, specifically FFA2 (GPR43) and FFA3 (GPR41). Acetate and propionate exhibit a higher potency for FFA2 than FFA3, while butyrate and other SCFAs have a lower potency for both (8) . FFA2 couples to G q and G i/o -proteins (9) and is expressed in rodent and human intestine, specifically in enteroendocrine L-cells (10) (11) (12) , that are thought to co-release the incretin and gastric emptying inhibitor, glucagon-like peptide 1 (GLP-1) (13) and the satietyinducing peptide YY (PYY). FFA2 knockout leads to impaired glucose tolerance and GLP-1 secretion (14) , and hyperphagia, obesity and insulin resistance (15) , therefore FFA2-mediated GLP-1 secretion may be of therapeutic benefit. Propionate stimulates GLP-1 secretion from murine colonic cultures and this response is impaired in cultures from FFA2-/-mice (14) .
Moreover, apically perfused intra-small intestinal or colonic administration of propionate to rats increases the release of, and elevates plasma GLP-1 and PYY (16) (17) while in hyperinsulinaemic humans, intracolonic acetate increases circulating GLP-1 and PYY (19) , confirming this SCFA's ability to release both L-cell products. The higher postprandial levels of these gut hormones observed post-RYGB are associated with improved glucose levels and satiety, indicating that upregulating these peptides may be beneficial in obese patients (19) .
PYY is released postprandially in direct response to nutrient ingestion (16) . Within the gastrointestinal (GI) tract PYY has a spectrum of activities, reducing gastric emptying and activating the ileal and colonic brakes in humans and rodents (20) (21). PYY also inhibits mucosal anion and fluid secretion along the length of the intestine, particularly in the distal bowel where L-cell frequency (22), and electrolyte absorptive capacity is greatest in mammals (23). In addition peripheral PYY acts to increase GLP-1 secretion and improve glucose tolerance (24), and is a well-known satiety factor. Indeed the development of PYY-Y2 anti-obesity agonists remains promising (25) (26).
GLP-1 inhibits gastric emptying and food intake, and is the principal incretin responsible for regulating postprandially elevated insulin secretion (27). GLP-1 mimetics are proven anti-diabetic agents (28) associated with improved glucose tolerance and reduced incidence of hypoglycemia, in addition to significant weight reduction (29). Identifying novel therapeutic targets that further promote GLP-1 release is a current focus of drug development programmes. FFA2-induced GLP-1 and PYY release has received much interest in recent years and FFA2 has been proposed as a promising target for the treatment of obesity and type-2 diabetes (30) (31). Nevertheless recent research shows that FFA2 acts in a cell-autonomous manner in β-cells to inhibit insulin secretion (32), raising doubts about its validity as a diabetes target. Figure S2C ). Furthermore it showed no significant enzymatic activity or radioligand displacement, when tested at 10 µM in a broad selectivity panel against 124 known drug targets and was not cytotoxic using our in-house assay. Thus we deem Cpd 1 suitable for use as an in vivo tool agonist for FFA2. Our primary aims were to determine the PYY and GLP-1 mechanisms underpinning L-cell FFA2 regulation of colonic mucosal function, and on intestinal and colonic transit, food intake and glucose tolerance in lean and diet-induced obese (DIO) mice, utilizing the FFA2 selective agonist Cpd 1 and FFA2-/-mice as tools.
RESEARCH DESIGN AND METHODS

Generation of FFA2-/-mice and Cpd 1 dosing
All experiments were performed in accordance with the Animals (Scientific procedures) Act 1986 and had approval from internal ethical committees for animal experimentation. FFA2-/-mice were generated on a 129/SvEv background as described previously (14) . For all in vivo studies the vehicle was 5:5:90 Tween 80:PEG400:saline at 5 ml/kg i.p.
GLP-1 secretion from primary mixed colonic cultures
The preparation of colonic cells from WT mice and secretion studies were performed as described previously (34) . Cpd 1 dissolved in DMSO was applied to the culture medium and incubated for 3 h at 37°C. Secreted and cellular GLP-1 was extracted as previously described (36) and active GLP-1 quantified by ELISA.
In vivo plasma active GLP-1 and insulin secretion
Mice were fasted for 14 h overnight before receiving either DPPIV inhibitor (DPPIVi) or vehicle and 30 min later were injected with Cpd 1 or vehicle. After 15 min mice received a liquid mixed nutrient meal challenge (Ensure Plus). Ten minutes later terminal plasma samples (via blood collected in aprotinin-coated tubes) were analysed using a Meso Scale Discovery Active GLP-1 Assay kit. Whole blood samples for insulin measurements were taken via tail bleed into heparinized capillary tubes and assayed by ELISA.
Mucosal ion transport (short-circuit current; I sc ) in vitro
Descending colon mucosa from WT or FFA2-/-male mice were bathed in Krebs-Henseleit (KH) buffer and voltage-clamped at 0 mV in Ussing chambers, as described previously (35) .
Vectorial ion transport was measured as I sc (μA.cm -2 ) and all peptide and antagonist additions were basolateral. Addition of Cpd 1 to the apical or basolateral reservoirs occurred 10 min after VIP (30 nM) and internal controls, i.e. PYY (10 nM) or exendin 4 (100 nM) were obtained following Cpd 1. Endogenous PYY or GLP-1 mediation in FFA2 activity was determined using optimised pretreatments i.e. the Y1 antagonist (BIBO3304, 300 nM) ± Y2 antagonist (BIIE0246, 1 µM) ± GLP-1 antagonist (exendin(9-39), 1 µM; (36)). In glucosesensitivity studies, colonic mucosa was bathed with KH containing glucose (11.1 mM) on the basolateral side but mannitol (11.1 mM) replaced glucose on the apical side, and apical FFA2 responses were recorded. As a control, blockade of the sodium/glucose co-transporter 1 (SGLT1) was achieved with apical phloridzin (50 µM).
Basal colonic transit in vivo
WT or FFA2-/-male mice acclimatized to handling for 3 days prior to experimentation were fasted overnight prior to testing. Either no drugs, Cpd 1 or vehicle was administered 10 min prior to bead insertion and colonic transit was measured using the propulsion assay described previously (36) .
Measurement of upper gastro-intestinal transit (UGIT)
WT or FFA2-/-mice acclimatized to handling for 3 days prior to experimentation were fasted for 16 h prior to testing. CD-1 mice were fasted for 4 h and then administered Cpd 1 or vehicle 10 min prior to testing. A charcoal meal (10% plant charcoal in 5% gum acacia; (21) was given by intragastric gavage and 30 min later the small intestine was isolated from the pyloric to ileocaecal junctions. UGIT, encompassing gastric emptying and small intestinal motility, was determined as described previously (36) .
In vivo diet-induced obesity (DIO)
C57Bl6, FFA2-/-or WT male mice (6-8 weeks old) received a high fat diet (HFD; 45% or 60% kcal as fat) for 21-23 weeks, as indicated. For the phenotyping study, bodyweight was monitored weekly and body composition assessed by EchoMRI. For the chronic dosing study mice were housed singly on a reverse phase light/dark cycle and received Cpd 1 or vehicle b.i.d. for 21 days; an OGTT was performed on day 22.
In vivo meal feeding
Lean mice were habituated to a 4 h daily presentation of wet-mash (wet powdered chow diet) over 2 weeks. On the study day standard chow was removed and mice were dosed with Cpd 1 or vehicle, 1 h before presentation the wet-mash meal. After 4 h, mash was replaced with standard chow.
Meal tolerance test (MTT) and oral glucose tolerance test (OGTT)
Mice were fasted overnight for 15 h. For compound studies animals were administered Cpd 1 or vehicle 1 h prior to challenge, consisting of 10 ml/kg p.o. liquid mixed nutrient meal challenge, 1.5 g/kg or 2 g/kg glucose p.o. as indicated. Tail snip blood samples were analysed for glucose either using a hand held monitor or standard enzyme assay and insulin by ELISA.
Data analysis
All data is presented as means ± 1SEM. Analyses were performed using GraphPad Prism 
RESULTS
Cpd 1 stimulates GLP-1 release from colonic cell cultures and systemically in the presence of a DPPIV inhibitor
Addition of Cpd 1 to primary colonic cultures increased GLP-1 secretion in a concentrationdependent manner, reaching significance at 10 µM, where there was a doubling of secretion compared to negative controls ( Figure 1A ). In comparison, the positive control (10 mM acetate) resulted in ~3-fold increase over negative control (vehicle).
In vivo Cpd 1 had no effect on plasma GLP-1 levels following nutrient challenge in the absence of a DPPIVi, but significantly increased GLP-1 when given in the presence of a DPPIVi ( Figure 1B ). In the absence of the DPPIVi, Cpd 1 caused a significant decrease in plasma insulin levels measured at a single timepoint 10 min after meal challenge, however no change was observed in the presence of the DPPIVi ( Figure 1C ). Figure 3F ). As previously observed (35) the SGLT1 inhibitor, phloridzin (used as a control) was only effective when apical glucose was present.
Cpd 1 mucosal responses in WT colon
In vivo colonic and upper GI transit is slowed by Cpd 1 in WT but not in FFA2-/-mice
Confirming that FFA2 receptors are involved in slowing GI motility, under basal conditions FFA2-/-mice exhibited a significantly faster colonic transit (i.e. reduced transit time) compared with that of WT mice ( Figure 3A) . In WT mice Cpd 1 significantly increased the time until bead expulsion compared to vehicle, and to an extent also in FFA2-/-mice (where a significant difference P < 0.05, was only observed using Student's t-test). The efficacy of Cpd 1 on FFA2-/-colonic transit was however significantly reduced compared to that of WT mice. Furthermore, basal UGIT in FFA2-/-mice was significantly faster than in WT mice and Cpd 1 significantly decreased UGIT in WT mice ( Figure 3B ). 
Cpd 1 decreases food intake in an in vivo meal feeding model
To investigate whether FFA2 activation affects food intake we tested the effect of Cpd 1 on meal feeding in lean WT mice. At 10 mg/kg Cpd 1 had no effect on food intake ( Figure 5A ).
However, at 30 mg/kg Cpd 1 resulted in a significant decrease in food consumed within 1 h after meal presentation and, between 4 -24 h, at the same dose. All mice appeared well with no signs of ill-health or malaise.
Cpd 1 decreases food intake and bodyweight in a mouse DIO model
To investigate whether the effects on food intake in lean mice translated into obese animals, the effects of Cpd 1 were tested in DIO mice. At 10 mg/kg there was no effect of Cpd 1 over the first 2 weeks of administration. Therefore the dose was increased to 20 mg/kg on day 14 and subsequently 30 mg/kg on day 17 ( Figure 5B ). At 20 mg/kg there was a small, but nonsignificant reduction in daily food intake. However, at 30 mg/kg the food intake was reduced by ~40% on the first day and this remained significantly lower than vehicle for the following 2 days. Corresponding to this reduction in food intake, a bodyweight loss was also seen ( Figure 5C ), significantly after the 30 mg/kg dose (day 19 and 20). Throughout the study mice appeared healthy, with no signs of ill-health or malaise.
Cpd 1 suppresses insulin levels and does not improve glucose tolerance in DIO mice
In DIO mice an acute dose of Cpd 1 significantly increased blood glucose between 30 -60 min in response to a MTT ( Figure 6A ). No change in the pre-meal glucose levels at time 0 was observed. By 90 min the blood glucose had returned to a level equivalent to vehicle. In the same mice insulin levels were significantly lower after Cpd 1 at 10 min ( Figure 6B ).
There was no difference at 60 min where the vehicle group's values had fallen back to a level similar to those given agonist.
Following chronic dosing of Cpd 1 to DIO mice an OGTT evoked a similar response on plasma glucose ( Figure 6C ) and insulin ( Figure 6D ) to that observed after an acute MTT.
There was no effect of Cpd 1 alone on basal glucose, but a significant elevation of blood glucose 30 min after meal challenge. A small but significant reduction in the basal insulin level was observed, but only prior to glucose challenge. Post-challenge there was a nonstatistically significant lower level of insulin in compound-treated animals. and PYY immunofluorescence (37) . Release profiles for these two hormones also differ postprandially and our data implicates differential mucosal PYY and GLP-1 release, as FFA2 agonism is predominantly PYY-mediated. In further support intraluminal oleic acid and butyrate infused into rat colon induced the release of PYY, but not GLP-1, although no effect on either peptide has also been reported (41) (42) Here DIO resulted in a higher proportion of fat mass and impaired glucose tolerance in FFA2-/-mice, although obese FFA2-/-and WT mice did not have different bodyweights.
In contrast, FFA2 deficiency exacerbated obesity in mice and SCFA-mediated FFA2 activation suppressed adipose insulin signalling, leading to inhibition of fat accumulation in adipose tissue (15) . We found that FFA2 agonism using Cpd 1 in DIO mice reduced freefeeding HFD food intake by approximately 40% on the first day of an effective dose (30 mg/kg) and this remained significantly lower than vehicle for the following 2 days, correspondingly a significant bodyweight loss was also seen at this dose. Similarly, Cpd 1 significantly reduced food intake in lean mice habituated to receive a daily palatable meal.
Although the pharmacokinetics of Cpd 1 are relatively short, the effects on food intake appear to remain after the compound is likely to be cleared; no rebound feeding effect was observed and following an acute dose a significant difference in food consumed was evident 4-24 h after administration; which may be due to downstream effects of FFA2 activation.
Our data suggests that Cpd 1 most likely exerts its anorexigenic effects by accelerating satiety through FFA2 and PYY-dependent mechanisms. In all feeding studies no signs of ill-health, malaise or sickness were observed and in the acute study it was noted that animals displayed characteristic satiety behaviours. Furthermore the pattern of anorectic effects was similar to sibutramine, a well-characterised anorectic agent in both acute and chronic models. Circulating PYY induces satiety, at least partially via Y2 receptors in the arcuate nucleus (49) . Targeted propionate delivery to the colon by oral ingestion increased plasma GLP-1 and PYY in a similar manner to a 1000 calorie meal and prevented weight gain in overweight humans (38) , thus the induction of satiety via activation of PYY mechanisms following Cpd 1 is likely after i.p. administration to mice. Cpd 1's mucosal PYY-mediated activity together with the reduced colonic motility in-vivo observed in FFA2-/-mice is congruent with the drug's anorectic action being most likely due to an increase in satiety, rather than an adverse effect of the compound. However, we have been unable to confirm that this effect is solely due to actions at FFA2 using FFA2-/-mice, as the background 129SvEv strain is not amenable to meal habituation. It is therefore possible that at least a small proportion of in vivo activity could be due to pharmacological activity at another unidentified receptor.
In DIO FFA2-/-mice no changes in insulin secretion were observed in response to the meal or glucose challenge, despite the significant glucose intolerance. This may be reflective of the severity of disease in this model as although obese, these mice only display mild glucose intolerance but not hyperinsulinaemia. Agonism of FFA2 in DIO mice dramatically suppressed insulin levels in response to a meal challenge, and although this may be an artefact response due to the timing of glucose and insulin measurements, blood glucose was elevated throughout the duration of the study indicating that insulin release was suppressed.
In agreement recent findings suggest that FFA2 receptors in pancreatic β-cells have a role in suppressing insulin release under diabetic conditions (32). Following chronic dosing of Cpd 1 to DIO mice over 21 days there was a significant reduction in the basal insulin levels prior to glucose challenge. This did not translate into an elevated basal glucose level, although a significant elevation of blood glucose 30 min after challenge was seen. Moreover no significant reduction in insulin release was observed, despite an evident trend. Taken together these data indicate that selective FFA2 agonists have no beneficial effect on glucose homeostasis during obesity.
In conclusion we describe the first reported use of a selective FFA2 agonist on ex vivo and in vivo responses. We have shown that proven FFA2 agonism has the potential to activate FFA2 receptors on L-cells and cause responses that are mediated by PYY release, therefore preferentially producing the beneficial effects of this gut hormone. These include in vivo activation of colonic and ileal brakes and suppression of food intake, leading to a reduction of bodyweight in DIO mice. However, in contrast to SCFAs, we were unable to detect any responses supporting GLP-1 secretion with Cpd 1 and Cpd 1 did not improve glucose tolerance in lean or obese mice, in fact it suppressed insulin levels in vivo. FFA2 agonists may have promising utility to treat obesity and consequently reduce the incidence of type-2 diabetes co-morbidity. However, therapies targeting FFA2 should be treated with caution given their effects on suppressing insulin secretion.
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Pharmacokinetics of Cpd 1
Cpd 1 was formulated in 1:99 Tween 80:Methylcellulose (0.5%, w/v in water) at a dose volume of 5 ml/kg i.p. and administered to C57Bl6 male. At pre-determined times thereafter animals were asphyxiated by a rising concentration of CO 2 and a terminal blood sample taken
